Radioimmunotherapy as Treatment for AML
Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.
Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.
Clinical Pearls
- Only 40% of patients with AML under the age of 60 are cured while only 10% of patients over the age of 60 are cured. The median survival is approximately 6 months.
- Radioimmunotherapy is one way that physicians can help develop more effective therapies while reducing toxicity.
- Initial studies used a beta-emitter but now physicians use alpha particles in therapy.
- By using alpha particles, physicians are able to target the tumor cell and do less damage to the surrounding normal tissue.
<<<
Recent Videos
Related Content
Tisa-cel Emerges as Earlier Option in Pediatric Acute Lymphoblastic Leukemia
September 5th 2024Article
The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.
Read More
